Key Highlights

• BTC Health reached a small profit in FY26.

• A key pharmaceutical supplier is in administration.

• Cardio products are carrying the company's growth.

• The supplier problem is described as contained.

BTC Health (ASX:BTC) is weighing the administration of a key pharmaceutical supplier against a cardio-led medical products Business that reached a small profit in FY26. The supplier problem is contained, because pharmaceuticals were only about A$1.1 million of a group that turned over about A$10.3 million.

What BTC Health does

BTC Health (ASX:BTC) Ltd is an ASX-quoted company, listed since August 2000, that describes itself as a Pooled Development Fund investing in Australian and New Zealand businesses that develop and distribute innovative medical products. Its ordinary shares trade under the code BTC.

In practice it operates as a distributor group, with divisions covering cardio, infusion pumps, neurospinal products and pharmaceuticals. The ASX company profile did not return a GICS sector, so the Health Care classification here rests on that business description.

The FY26 result

For the year ended 30 June 2026, BTC reported consolidated Revenue of $10,271,312, against $10,232,894 a year earlier. The announcement does not name a currency, but BTC is an Australian company.

Statutory profit after tax was $34,728, down from $3,981,298 in FY25. The announcement does not explain that gap, so it should not be read as a like-for-like decline in trading. Consolidated EBITDA improved to $137,721 from $2,770, and gross Margin edged up to 42.5 per cent from 42.2 per cent.

Group cash was $2.08 million at 30 June 2026, compared with $1.29 million a year earlier. A Placement of about $1.96 million completed in December 2025 helped fund that position.

Cardio carries the growth

Cardio revenue rose 31 per cent to $5.86 million and now makes up 57 per cent of group sales. Revenue from Corcym heart valves rose 91 per cent to $2.34 million, while PEARS aortic root support implants grew 20 per cent to $1.10 million. Cardiopulmonary bypass cannulas added $0.73 million in their first year.

Other lines were weaker. ECMO revenue from Eurosets fell to $1.60 million from $2.29 million, which BTC attributed to delayed purchase orders from State public hospitals. Infusion pump revenue fell 35 per cent to $1.92 million as customers move from discontinued ambIT pumps to replacement models.

In February 2026 BTC also secured exclusive Australian and New Zealand distribution rights for Jafron Biomedical hemoperfusion cartridges. The agreement contributed little to FY26 and is expected to build during FY27.

The Arna Pharma administration

On 7 September 2026, Arna Pharma Pty Ltd entered voluntary administration. Arna manufactures Bronchitol and Aridol at a single Sydney facility, and BTC Pharma, a wholly owned subsidiary, is the Australian sponsor and exclusive distributor of both.

BTC said neither it nor BTC Pharma is a shareholder, lender, guarantor or related party of Arna, and that its exposure is limited to ordinary Supply arrangements. It holds about eight months of Bronchitol stock but less than one month of Aridol.

Combined sales of the two products were $1.1 million in FY26. Without further supply, BTC expects FY27 sales of up to $0.5 million. Arna has said it intends to recapitalise, but BTC said it cannot verify that.

Risks and what to watch

Concentration is the central risk. A smaller revenue base means a single lost product, or slow State hospital procurement for ECMO, can swing results. Profitability is also thin, with adjusted EBITDA of $267,224.

BTC's published net Tangible Asset backing at 30 September 2026 was 3.09 cents per share on a board valuation, with unlisted securities making up most of the total. Those holdings are valued by directors rather than a market price.

The next dated event is the annual general meeting, held virtually at 3:00 pm AEDT on 19 November 2026. Resolutions include electing new director Ian Kadish and an option grant to the executive chair. Further updates on Arna supply are also promised by the company.